Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative antibiotic strategy for asymptomatic bacteriuria in patients undergoing intravesical botulinum toxin A injections
2022-000259-35Phase 3Active
- Sponsor
- CHU de Lille
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of botulinum toxin type A in overactive bladder (OAB), detrusor hyperreflexia (DH), multiple sclerosis (MS) and 2 more (2 arms), sponsored by CHU de Lille. Primary endpoint: Rate of patients with symptomatic urinary tract infection within 6 weeks after intravesical botulinum toxin A injections. Started Mar 2022; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)detrusor hyperreflexia (DH)multiple sclerosis (MS)spinal cord injury (SCI)asymptomatic bacteriuria (ASB)
Beyond the preview
Go deeper on 2022-000259-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000259-35.